Research Topics
| J D CampbellSummaryAffiliation: University of Maryland Country: USA Publications
| Collaborators
|
Detail Information
Publications
Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIVJames D Campbell
Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda
Am J Prev Med 44:S63-9. 2013..PrEP is generally safe and effective and may be cost effective in a targeted population. Awareness and interest in PrEP are increasing. PrEP is an important new addition to HIV prevention services, but continued study is warranted...
Timing of therapy for latent tuberculosis infection among immigrants presenting to a U.S. public health clinic: a retrospective studyKathleen R Page
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
BMC Public Health 8:158. 2008..Current guidelines recommend screening and treatment for latent TB infection (LTBI) within 5 years of arrival to the U.S. This study evaluates the timing of LTBI therapy among immigrants presenting for care to a public health TB clinic...- U.S. medical resident familiarity with national tuberculosis guidelinesPetros C Karakousis
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
BMC Infect Dis 7:89. 2007..We assessed medical resident knowledge about tuberculosis diagnosis and early management based on American Thoracic Society guidelines... 
Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adultsJames D Campbell
University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
Hum Vaccin 3:205-11. 2007..Although an anthrax vaccine is currently licensed in the USA, better vaccines are desirable for both pre- and post-exposure prophylaxis...- Pandemic flu vaccine: are we doing enough?J D Campbell
University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland, USA
Clin Pharmacol Ther 82:633-5. 2007..Below I discuss some truly phenomenal advances that have emerged from this newfound interest in pandemic influenza, to show that, yes, we are doing enough... - Invasive pneumococcal infections among hospitalized children in Bamako, MaliJames D Campbell
University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD 21201, USA
Pediatr Infect Dis J 23:642-9. 2004..Prevention of invasive pneumococcal disease (IPD) in children is a global public health priority, and determination of the most common serotypes is crucial for vaccine development and implementation... - The causes of hospital admission and death among children in Bamako, MaliJames D Campbell
University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
J Trop Pediatr 50:158-63. 2004..Prospective surveillance using microbiological data is needed to delineate the organism-specific burdens... - Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adultsJames D Campbell
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
J Infect Dis 186:1848-51. 2002.... - Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infantsJames D Campbell
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Pediatr Infect Dis J 21:822-6. 2002.... - Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccineJakub K Simon
Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA
Clin Vaccine Immunol 18:355-61. 2011.... - A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adultsJakub K Simon
Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
Hum Vaccin 3:54-8. 2007..Mucosal administration of currently licensed measles vaccine has been proposed to address issues of needle safety and improve vaccine uptake... - Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adultsKaren L Kotloff
Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Infect Immun 70:2016-21. 2002..We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 10(3) to 10(6) CFU but elicits clinical reactions that must be assessed in further volunteer trials... - Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trialKaren L Kotloff
Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA
JAMA 292:709-15. 2004..Group A streptococcal infections and their sequelae represent a global health problem. Recent advances have allowed previous obstacles associated with group A streptococcal vaccine development to be overcome... - Needle-free vaccine deliveryErin L Giudice
Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Room 480, Baltimore, MD 21201, USA
Adv Drug Deliv Rev 58:68-89. 2006..Improved knowledge regarding the immune system and its responses to vaccination continues to inform vaccine technologies for needle-free vaccine delivery... - The use of experimental drugs during national crisisAdil E Shamoo
University of Maryland School of Medicine, Baltimore, MD 21201, USA
Account Res 10:69-84. 2003 - Genotypic analysis of invasive Streptococcus pneumoniae from Mali, Africa, by semiautomated repetitive-element PCR and pulsed-field gel electrophoresisS M Harrington
Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA
J Clin Microbiol 45:707-14. 2007..The data support that serotypes 2 and 5 were likely to be the result of dissemination of particular clones, some of which are responsible for invasive disease over a broad population range... - Overview of vaccines and immunisationMyron M Levine
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Br Med Bull 62:1-13. 2002 - Rapid licensure of a new, inactivated influenza vaccine in the United StatesJohn J Treanor
University of Rochester, Rochester, New York 14642, USA
Hum Vaccin 1:239-44. 2005..We evaluated a split virus TIV (Fluarix, GSK), to generate data supportive of a license application in the US... - Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccineSamba O Sow
, Mali (CVD-Mali
Pediatr Infect Dis J 24:533-7. 2005..5% to ceftriaxone. CONCLUSIONS: The substantial burden of invasive Hib disease documented in Bamako has prompted the Malian government to introduce routine infant immunization with Hib conjugate... - Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccineJohn J Treanor
Department of Medicine, University of Rochester, Rochester, NY, USA
N Engl J Med 354:1343-51. 2006..Influenza A (H5N1) viruses could cause a severe worldwide epidemic, with high attack rates, large numbers of deaths and hospitalizations, and wide disruption. Effective vaccines against these viruses in humans are urgently needed... - Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humansKenneth M Zangwill
University of California, Los Angeles, CA, USA
J Infect Dis 197:580-3. 2008..5-mug-dose groups had a MN GMT > or =1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose. (Trial registration: Clinical Trials.gov identifier NCT00240968 .)... - Vaccines to protect humans from pandemic avian influenza strainsJames D Campbell
University of Maryland Center for Vaccine Development, Baltimore, USA
Md Med 7:15-8. 2006..No efficacy studies have yet been performed. Future efforts will be directed toward adjuvants, different routes of administration, newer manufacturing methods, and possibly new viral targets...